FMP
Aug 14, 2025 6:04 PM - Rayan Ahmad
Image credit: Google Images
UBS Group AG, trading on the NYSE under the symbol UBS, is a global financial services company headquartered in Switzerland. It offers a wide range of services, including wealth management, asset management, and investment banking. UBS competes with other major financial institutions like Credit Suisse and Deutsche Bank. On August 14, 2025, Deutsche Bank maintained its "Buy" rating for NYSE:UBS, with the stock priced at approximately $39.67.
Cevian Capital, an activist investor, has shown increased confidence in UBS by raising its share stake by 9.9% during the second quarter, as highlighted in a regulatory filing. This move indicates Cevian Capital's belief in UBS's performance and future prospects. The stock is currently priced at $39.67, reflecting a slight increase of 0.04%, or $0.015.
UBS's stock has seen fluctuations today, with a low of $39.51 and a high of $39.78, which is also its highest price over the past year. The lowest price for UBS in the past year was $25.75. This range demonstrates the stock's volatility and potential for growth, which may have influenced Deutsche Bank's decision to maintain its "Buy" rating.
The company has a substantial market capitalization of approximately $125.71 billion, indicating its significant presence in the financial sector. With a trading volume of 635,046 shares, UBS remains an actively traded stock, attracting interest from investors like Cevian Capital. This level of activity and market cap underscores the bank's strong position in the industry.
Aug 14, 2025 2:00 PM - Andrew Wynn
CleanTech Vanadium Mining Corp. (NYSE:CTV) is making waves with its recent acquisition of fluorspar projects in the Illinois-Kentucky Fluorspar District. This strategic move, costing $4 million, positions CleanTech as a major player in the U.S. fluorspar market. The acquisition involves a binding op...
Aug 14, 2025 3:00 PM - Rayan Ahmad
Traws Pharma, Inc. (NASDAQ:TRAW) is a pharmaceutical company focused on developing treatments for respiratory viruses, including SARS CoV2 and influenza. The company is working on ratutrelvir, a ritonavir-free protease inhibitor, and Tivoxavir marboxil (TXM) for influenza. TRAW's competitors include...